The design of synthetic peptide analogues offers potential to overcome several inherent limitations of natural peptides, including rapid degradation, poor permeability and adverse effects.
This webinar will discuss key absorption, distribution, metabolism and excretion (ADME) characteristics in peptide drug development, showcasing in-vitro data from representative examples across different peptide classes, including natural peptides, hormones, cyclic peptides, GLP-1 analogues and synthetic D-amino acid peptides.
Attendees will gain insights into the key ADME properties that influence novel peptide therapeutics, with a focus on:
- Evaluation of peptide stability in biological matrices (plasma, liver, intestine, kidney) and resistance to proteases
- Mechanisms of protease resistance and strategies for improving metabolic stability
- Assessment of in-vitro permeability and factors affecting absorption
This webinar is ideal for professionals involved in peptide drug development, formulation scientists, pharmacokinetic experts and anyone interested in advancing the stability and performance of peptide-based therapeutics.
Register for this webinar to gain valuable insights into ADME properties across diverse peptide classes and discover strategies to enhance metabolic stability and drug-like performance.
Speaker
Dr. Haoqing Chen, PhD, Lead of ADME, BioDuro
Dr. Haoqing Chen is a highly accomplished scientist with a strong academic and industrial background in chemistry and the life science industry. She earned her undergraduate degree in Chemistry from Sun Yat-Sen University and subsequently completed her PhD in Chemistry at the University of Houston, where her research focused on click reactions and bioconjugation.
Following her PhD, she served as a Postdoctoral Researcher at the University of Minnesota’s College of Pharmacy for over two years, specializing in carcinogen studies related to DNA adduct formation. She then joined Stanford University’s School of Medicine as a Research Scientist, where she dedicated more than two years to studying metabolomics and gut microbiota metabolism.
Currently, Dr. Chen is at BioDuro, where she has been leading the ADME group within the DMPK department for over three years, significantly contributing to drug discovery and developme
Message PresenterWho Should Attend?
This webinar will appeal to research professionals from pharmaceutical and biotech companies involved in drug discovery, drug development as well as Primary Investigators of academic labs:
- C-Level
- Senior/Director
- Manager
- DMPK Scientists
- Consultants
What You Will Learn
Attendees will learn about:
- Stability in physiological environments and protease susceptibility
- Enhanced metabolic stability and membrane permeability
- Structural modifications impacting half-life
- Protease resistance and improved stability
Xtalks Partner
BioDuro
BioDuro, an Advent International portfolio company, is a CRDMO with a 29-year proven track record. Headquartered in Irvine, California, USA, our global presence spans 7 sites across the United States and China, with over 2,000 employees. Specializing in both small and large molecule discovery, development, scale-up, and manufacturing, we offer fully integrated services from early drug discovery to commercial manufacturing across chemistry, biology, DMPK, drug substance, and drug product. For more information, please visit https://www.bioduro.com
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account